NASDAQ:ACET

Biotechnology·Finance·NASDAQ:ACET·News·Stock Market

Adicet Bio Shares Halted Ahead of Data Readout That May Steer ACET

Adicet Bio shares closed at $8.30 Friday, up 5.2%, before U.S. markets shut for Memorial Day. Investors await Phase 1 data for prula-cel in lupus nephritis and systemic lupus erythematosus, expected by mid-2026. The company reported a Q1 net loss of $20.2 million and held $137.6 million in cash as of March 31. Trading resumes Tuesday.

May 25, 2026

Genomic Test Could Spare Millions of Breast Cancer Patients Chemotherapy, Landmark Study Finds
May 29, 2026, 8:16 PM EDT. A landmark study reveals that millions of breast cancer patients could safely skip chemotherapy thanks to the Prosigna genomic test, which analyses tumor genes to assess recurrence risk. The international OPTIMA trial, involving 4,429 patients, showed a 93.7% five-year cancer-free survival rate for those who avoided chemotherapy, nearly matching the 94.9% rate for those treated with it. Karen Bonham, a trial participant, described her relief upon learning she would not need chemotherapy, attributing her cancer-free status nine years post-diagnosis to the test's guidance. Experts hail the findings as gamechanging, potentially transforming breast cancer treatment by reducing unnecessary chemotherapy and its side effects, while maintaining patient safety.